dc.description.abstract |
Glimepiride and Atorvastatin in combination are commonly employed for treating the hyperglycemia and
dyslipidemia, respectively, in patients of type 2 diabetes. The present study was designed to find out the influence of
Atorvastatin on urinary excretion and renal clearance of Glimepiride in healthy adult male volunteers. In each
experimental subject, Glimepiride 2mg was given orally after an overnight fasting. Samples of blood and urine were
taken at different specific time intervals. After a washout period of ten days, Glimepiride 2mg was co-administered with
Atorvastatin 20mg orally. Post-medication, blood and urine samples were collected following the same sampling
schedule as for Glimepiride alone. The samples were analyzed for Glimepiride and creatinine concentration by HPLCUV and Spectrophotometer, respectively. Mean (±SE) values for blood pH 7.445±0.05 and 7.382±0.05, urine pH
4.972±0.08 and 5.08±0.10, diuresis 0.0207±0.00 and 0.0237±0.00ml/min/kg, endogenous creatinine in plasma
9.048±0.33 and 8.613±0.024µg/ml, endogenous creatinine in urine 512.34±18.20 and 556.72±4.60µg/ml, Glimepiride
plasma concentration 0.16069±0.00 and 0.3227±0.01µg/ml, Glimepiride urine concentration 1.5994±0.03 and
0.8665±0.04µg/ml, renal clearance of creatinine 1.224±0.09 and 1.550±0.09ml/min/kg, renal clearance of Glimepiride
0.2064±0.01 and 0.0641±0.00ml/min/kg and clearance ratio 0.1791±0.01 and 0.0414±0.00 were observed for
Glimepiride alone and its concurrent administration with Atorvastatin, respectively. Atorvastatin decreased the urinary
excretion and renal clearance of Glimepiride due to which chances of hypoglycemia provokes and renal handling of
Glimepiride involves back diffusion besides glomerular filtration and no influence of Atorvastatin was seen on these
mechanisms. |
en_US |